$20.77 (2.42%)

Volume: 865.459k

Closed: Dec 02, 2022

Hollow Logo Score: 0.671

Fate Therapeutics Stock Forecast

$20.77 (2.42%)

Volume: 865.459k

Closed: Dec 02, 2022

Score Hollow Logo 0.671

Fate Therapeutics Stock Statistics NASDAQ:FATE

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior. Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average. Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Dates Signal Change
2022-12-02 - 2022-12-02 HOLD 0
2022-12-01 - 2022-12-02 SELL 2.42
2022-11-30 - 2022-12-01 BUY -1.99
2022-11-29 - 2022-11-30 HOLD 4.90
2022-11-16 - 2022-11-29 SELL -3.78

Stock Score Effectiveness

Bollinger Stock Signal Effectiveness

Macd Signal Effectiveness

Mv7 Signal Effectiveness

Score signal

Bollinger Signal Statistics

MV signal statistics

MACD Signal Statistics

Hot Stocks To Watch:

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul... FATE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT